Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Non-Adherence to Endocrine Therapy for BC

Breast Cancer Res Treat; ePub 2016 Apr 16; Hershman, et al

Women with breast cancer who reported a better attitude toward endocrine therapy (ET), better quality of life, and more treatment satisfaction were less likely to be ET non-persistent compared to those who reported intrusive/avoidant thoughts. This according to a cohort study of 523 women with breast cancer and a subset of patients treated with ET between 2006 and 2010. Researchers found:

• 94 women (18%) were non-persistent over a 2-year follow-up.

• Women in the highest income category had lower odds of being non-persistent (OR=0.43).

• Quality of life and attitudes toward ET at baseline were associated with non-persistence.

• Most of the women in the study continued ET.

Citation: Hershman DL, Kushi LH, Hillyer GC, et al. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). [Published online ahead of print April 16, 2016]. Breast Cancer Res Treat. doi:10.1007/s10549-016-3788-x.